Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Investment losses are painful at any point, but losing stocks are even harder to stomach when the market is in the midst of a ...

Gilead Sciences, Inc. today announced that the company's Board of Directors has declared an increase of 2.6% in the company's quarterly cash dividend, beginning in the first quarter of 2025. The ...

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...